

Supporting information

Synthesis of Valuable Aromatics from Bioderived 5-Hydroxymethylfurfural (HMF) under Mild Conditions

Shasha Zheng, Bartosz Wozniak, Fabian Kallmeier, Eszter Baráth, Sergey Tin*, and Johannes G. de Vries*

*Corresponding author

E-mail: Johannes.deVries@catalysis.de; Sergey.Tin@catalysis.de


Contents

1. General remarks	3
2. Synthesis of DOH from HMF.....	3
3. Base-catalyzed intramolecular aldol condensation of DOH.....	5
4. Proline and derivatives catalyzed intramolecular aldol condensation of DOH.....	6
5. Thiourea catalyzed intramolecular aldol condensation of DOH	7
6. Condition optimization for the formation of 1,4-dipyrrolidinylbenzene (2a) and 4-pyrrolidinylphenol (3a)	8
7. General procedures for the reactions of DOH and Amines	11
8. Mechanism studies.....	19
9. Drug molecules containing <i>N</i> -phenylpiperiziny moiety ⁴⁻⁷	22
10. Acid-catalyzed intramolecular Aldol condensation of DOH	23
11. Condition optimization for the conversion of DOA to catechol.....	25
Appendix I: NMR spectra.....	27
References.....	56

1. General remarks

5-Hydroxymethylfurfural (HMF) was purchased from AVA-Biochem BSL AG and used directly without further purification. All other commercially available reagents were purchased from Sigma-Aldrich, Strem, TCI, and ABCR. Solvents used in reactions were obtained from Acros Organics, or a solvent purification system (MBraun SPS). All solvents used for work-up or column chromatography were purchased from Walter. ^1H , ^2H and ^{13}C NMR spectra were recorded on a Bruker Fourier 300, a Bruker AV300, or a Bruker AV400 MHz spectrometer. Chemical shifts are given in ppm and related to residual solvent peaks.¹ High resolution mass spectroscopy was performed on an Agilent 6210 Time-of-Flight (SICRIT ionization, 15 kHz, 1600 V) or a Thermo Electron MAT 95-XP (EI, 70 eV).

2. Synthesis of DOH from HMF




The synthesis followed the reported procedure²: To a 300 mL Hastelloy autoclave was added 5-HMF (2.5 g, 20.0 mmol), 100 mL phosphate-buffered saline solution (PBS) (pH = 2.49), Ir catalyst (8.0 mg, 0.075 mol%), and a magnetic stirring bar. The autoclave was flushed with N_2 three times, H_2 twice, and pressurized with 30 bar H_2 . The reaction was stirred at 140 °C for 1 hour (temperature achieved after 30 mins). The reaction was allowed to cool down to room temperature and the solvent was removed by evaporation. The crude product was purified through column chromatography (silica gel) using ethyl acetate/cyclohexane (1/1 to 3/1) as eluent to give a yellow solid. Further recrystallization with CH_2Cl_2 and pentane under -20 °C gave the desired HHD (1.8 g, 70%) as yellow needles.


To a 1 L Schlenk flask was added HHD (10.0 mmol, 1.3 g), MS 4 Å (powdered, 2 g), and a magnetic stirring bar. The flask was evacuated for 0.5 h and then flushed with O_2 three times. To the flask equipped with an O_2 balloon was added dry MeOH (80 mL), $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (5 mol%, 186 mg), and pyridine (10 mol%, 81 μL). The reaction was stirred at room temperature for 100 mins. The reaction mixture was filtered and diluted with 200 ml DCM. Subsequently, this mixture was washed with 20 ml NaEDTA solution (1% in H_2O) followed by 10 ml NaEDTA solution (1% in H_2O , prepared by neutralizing 1g of EDTA in 100 ml H_2O with sodium hydroxide). Then the blue-green aqueous solution was counter-extracted using DCM (2 x 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate. Removal of the solvent through evaporation afforded 1.2 g (93%) of a yellow oil.

Although GC and TLC both showed high purity of DOH after purification, ^1H NMR spectra in CDCl_3 , CD_2Cl_2 , CD_3CN , d_6 -DMSO, and d_8 -THF all were ambiguous, which is due to the high reactivity of DOH. In d_8 -toluene, the solubility of DOH was very poor. Under acidic conditions in the presence of H_2O , DOH converted to 2,5-dioxohexane-1,1-diol (shown below), which was confirmed by GC. In


CD₃OD, recognizable NMR spectra were obtained, showing the structure of 2,5-dioxohexanediol. ¹H NMR (300 MHz, CD₃OD): δ (ppm) 4.78 (s, 1H), 3.35 (s, 2H), 2.81-2.87 (m, 2H), 2.72-2.77 (m, 2H), 2.17 (s, 3H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 209.8, 206.9, 98.5, 37.3, 32.1, 29.7.



GC of DOH




GC of DOH in acidic solution




3. Base-catalyzed intramolecular aldol condensation of DOH

Table S1: Reactions of DOH under basic conditions



Entry	Bases	Solvent	<i>T</i>	Time	Results ^a
1 ^b	KOH			1.5 h	No desired product
2 ^b	NaHCO ₃				No reaction
3 ^b	TMG			3 h	No reaction
4 ^b	Cs ₂ CO ₃	THF	RT		Levulinic acid
5 ^b	DMAP			0.6 h	Complex mixture, no desired product
6 ^b	Na ₂ CO ₃			2 h	Complex mixture, no desired product
7 ^b	TBD			3.5 h	No desired product
8		Toluene		6 h	
9		THF			Complex mixture, no desired product
10	DMAP	<i>i</i> -PrOH		7 h	
11		DCM			
12		MeOH			Levulinic acid
13		Toluene			
14		THF		6 h	Complex mixture, no desired product
15	DBU	<i>i</i> -PrOH	- 40 °C to		
16		DCM	RT		
17		MeOH		7 h	Levulinic acid
18		Toluene			
19		THF		6 h	Complex mixture, no desired product
20	DABCO	<i>i</i> -PrOH			
21		DCM			No reaction
22		MeOH		7 h	Partly converted to levulinic acid
23	DABCO		40 °C		No desired product
24	DMAP	<i>i</i> -PrOH	40 °C		
25	(NPCI ₂) ₃		80 °C		
26	<i>t</i> -BuOK		40 °C	2 h	Complex mixture, no desired product
27	DABCO		40 °C		
28	DMAP	<i>t</i> -BuOH	40 °C		
29	(NPCI ₂) ₃		80 °C		No reaction
30	<i>t</i> -BuOK		40 °C		Complex mixture, no desired product
31 ^c	K ₂ CO ₃				Mixture of levulinic acid and methyl
32 ^c	Cs ₂ CO ₃	MeOH	RT	0.5 h	levulinate
33 ^c	KOH				


Reaction conditions: DOH (0.2 mmol), Base (1.0 equiv), solvent (1 mL), under Ar. ^aAnalyzed by GC, NMR, TLC, and/or GC-MS. ^bUnder air. ^cBase (16.0 equiv), MeOH (60 mL).



General procedure for Table S1: to a 4 mL vial was added DOH (0.2 mmol, 25 mg) and a magnetic stirring bar. The vial was sealed with a septum and flushed with Ar. Solvent (1 mL) and base (1.0 equiv) were added under Ar. The reaction was stirred at the specified temperature for the specified time.


4. Proline and derivatives catalyzed intramolecular aldol condensation of DOH

Table S2: Reactions of DOH catalyzed by proline and various derivatives



Entry	Conditions	Solvent	Time	Results ^a
1	DL-proline (25 mol%)	<i>i</i> -PrOH	48 h	
2		DMSO		
3		DMF		
4		H ₂ O		
5	DL-proline (25 mol%)	DCM		
6	HOAc (0.5 equiv)	<i>i</i> -PrOH		
7		MeOH		
8		THF	19 h	No reaction
9	DL-proline (25 mol%)	DCM		
10	TFA (0.5 equiv)	<i>i</i> -PrOH		
11		MeOH		
12		THF		
13	DL-proline (25 mol%)	DCM		
14	PTSA · H ₂ O (0.5 equiv)	<i>i</i> -PrOH		
15		MeOH		
16		THF		
17	S1 (20 mol%)	DMSO	19 h	No reaction
18		DMF		No desired product, complex mixture,
19		H ₂ O	9 h	S5 was observed.
20	S1 (50 mol%)	H ₂ O		
21 ^b	L-proline (50 mol%)	DMF/H ₂ O	4 h	No reaction
22 ^b	S1 (50 mol%)	(1/1)		No desired product, complex mixture,
23 ^b	S2 (50 mol%)			S5 was observed.
24	S1 (50 mol%), 2.5 h; then PTSA (1.0 equiv), 2.5 h	H ₂ O	2.5 h	No reaction
25	S1 (50 mol%), 2.5 h; then pyridine (1.0 equiv), 2.5h	H ₂ O		No desired product, complex mixture, S5 was observed.
26	S3 (50 mol%)	MeOH	17 h	
27		DCM		No desired product, complex mixture, S5 was isolated (yield: 4%).
28	S3 (50 mol%), pyridine	H ₂ O	2 h	No desired product, complex mixture,
29	(1.0 equiv)	DCM		S5 was observed.
30	S3 (1.0 equiv), pyridine	H ₂ O		
31	(1.0 equiv)	DCM		
32	Pyrrolidine (25 mol%)	THF	19 h	4-pyrrolidylphenol was detected.
33	Pyrrolidine (1.0 equiv)	THF	2 h	1,4-dipyrrolidinylbenzene, 4-pyrrolidylphenol
34	S4 (50 mol%)	DCM	2 h	No desired product
35 ^c	L-proline (2.0 equiv)			No desired product
36 ^c	S1 (2.0 equiv)	DMF	2 h	No desired product, complex mixture,
37 ^c	S3 (2.0 equiv)			S5 was observed.

Reaction conditions: DOH (0.3 mmol), solvent (300 μ L), Cat., base or acid, under Ar, stirred at room temperature. ^aAnalyzed by GC, ¹H NMR, TLC, and GC-MS. ^bDMF (300 μ L), H₂O (300 μ L). ^c80 °C.




General procedure for Table S2: to a 4 mL vial was added DOH (0.3 mmol, 38 mg) and a magnetic stirring bar. The vial was sealed with a septum and flushed with Ar. Solvent (300 μ L), cat., and additives were added under Ar. The reaction was stirred at room temperature (unless mentioned otherwise).

1-(1*H*-pyrrol-1-yl)hexane-2,5-dione (S5). To a 50 mL Schlenk flask under Ar was added DOH (5.0 mmol, 640 mg), a magnetic stirring bar, DCM (5 mL), and (*R*)-4-TBSO-*L*-proline **S3** (0.5 eq, 614 mg). After stirring at room temperature for 90 mins, the reaction solvent was removed through evaporation. Column chromatography (SiO₂, DCM) afforded **S5** as yellowish oil (12 mg, 4%). ¹H NMR (300 MHz, CD₃OD) δ (ppm) 6.64 (t, *J* = 2.1 Hz, 2H), 6.09 (t, *J* = 2.1 Hz, 2H), 4.80 (s, 2H), 2.73-2.77 (m, 2H), 2.55-2.59 (m, 2H), 2.14 (s, 3H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 209.8, 207.5, 122.9, 109.5, 37.7, 33.5, 29.6. MS-EI (*m/z*): 179 (32%), 136 (4%), 99 (44%), 80 (100%), 71 (8%), 53 (20%), 43 (25%).

5. Thiourea catalyzed intramolecular aldol condensation of DOH


Table S3: Reactions of DOH catalyzed by thiourea catalysts



Entry	Cat.	Solvents	<i>T</i>	<i>t</i>	Results ^a
1	S6	DCM	RT	overnight	No reaction
2		THF	RT, 24 h; then at 40 °C, 24 h		
3		MeOH	RT	24 h	Full conversion, no desired product.
4		DCM			No reaction
5	S7	THF	RT, 24 h; then at 40 °C, 24 h		
6		MeOH	RT	24 h	No reaction
7		DCM			
8	S8	THF	RT, 24 h; then at 40 °C, 24 h		
9		MeOH	RT	24 h	Full conversion, no desired product.
10		DCM			
11	S9	THF	RT, 24 h; then at 40 °C, 24 h		No reaction
12		MeOH	RT	24 h	
13		DCM			Full conversion, no desired product.
14	S10	THF	RT, 24 h; then at 40 °C, 24 h		
15		MeOH	RT	24 h	
16		DCM			Full conversion, no desired product.
17	S11	THF			
18		MeOH	RT, 24 h; then at 40 °C, 24 h		

19		DCM			
20	S12	THF	RT	72 h	No reaction
21	S10	MeCN	RT	24 h	Full conversion, no desired product.
22			reflux	5 h	


Reaction conditions: DOH (0.2 mmol), Cat. (15 mol%), solvent (1 mL). ^aAnalyzed by GC, ¹H NMR, TLC, and/or GC-MS.



General procedure for Table S3: to a 4 mL vial was added DOH (0.2 mmol, 25 mg), cat. (15 mol%), a magnetic stirring bar, and solvent (1 mL). The vial was sealed with a cap and the reaction was stirred at the specified temperature for the specified time.

6. Condition optimization for the formation of 1,4-dipyrrolidinylbenzene (2a) and 4-pyrrolidinylphenol (3a)

Table S4. Solvent screening for 3a and 2a




Entry	Solvent	3a (%)	2a (%)	Total (%) ^a
1	THF	2	18	20
2	Dioxane	2	18	20
3	Toluene	2	15	17
4 ^b	Toluene	0	2	2
5	Et ₂ O	2	13	15
6	MTBE	1	9	10
7	H ₂ O	0	0	0
8	Acetone	0	0	0
9	DMF	9	8	17
10	DMSO	5	11	16
11	CDCl ₃	2	3	5
12	Pyridine	1	17	18

Reaction conditions: DOH (0.1 mmol), pyrrolidine (2.0 equiv), solvent (0.5 mL), rt, overnight. ^aYield determined by GC using dodecane as internal standard. ^bToluene (5 mL).

General procedure for Table S4: to a 4 mL pressure tube was added DOH (0.1 mmol, 13 mg), solvent, a magnetic stirring bar, and pyrrolidine (2.0 equiv, 16 μ L). The pressure tube was sealed and stirred at room temperature overnight. Then, dodecane was added as internal standard for GC measurement.

Table S5. Optimization of additives and concentration for 3a and 2a




Entry	Pyrrolidine (equiv)	Additives	THF	3a (%)	2a (%)	Total (%) ^a
1	2.0	-	0.5 mL	2	18	20
2 ^b	2.0	-	0.5 mL	7	9	16
3	2.0	-	2 mL	3	14	17
4	2.0	-	5 mL	1	0	1
5	2.0	-	0.1 mL	2	9	11
6	2.0	-	0.2 mL	2	13	15
7	1.0	-	0.5 mL	3	5	8
8	4.0	-	0.5 mL	0	3	3
9	3.0	-	0.5 mL	0	4	4
10	2.0	HCl (aq.)	0.5 mL	1	0	1
11	2.0	TFA	0.5 mL	6	2	8
12	2.0	HOAc	0.5 mL	4	11	15
13	2.0	PTSA·H ₂ O	0.5 mL	4	1	5
14	2.0	pyridine	0.5 mL	1	15	16
15	2.0	Na ₂ CO ₃	0.5 mL	2	14	16
16	2.0	DMAP	0.5 mL	1	10	11
17^b	2.0	TFA	0.5 mL	15	4	19
18^b	2.0	HOAc	0.5 mL	9	21	30
19 ^c	2.0	TFA	0.5 mL	9	2	11
20 ^c	2.0	HOAc	0.5 mL	12	11	23

Reaction conditions: DOH (0.1 mmol), pyrrolidine (2.0 equiv), THF, additives (1.0 equiv), rt, overnight.

^aYield determined by GC using dodecane as internal standard. ^b66 °C. ^c1,4-dioxane, 101 °C.

General procedure for Table S5: to a 4 mL pressure tube was added DOH (0.1 mmol, 13 mg), THF, a magnetic stirring bar, additive (1.0 equiv), and pyrrolidine (2.0 equiv). The pressure tube was sealed and stirred at the specified temperature overnight. Then, dodecane was added as internal standard for GC measurement.

Table S6. Optimization of pyrrolidine and HOAc for 3a and 2a




Entry	Pyrrolidine (equiv)	HOAc (equiv)	3a (%)	2a (%)	Total (%) ^a
1	1.5	1.0	10	7	17
2	2.0	1.0	13	7	20
3	2.25	1.0	7	14	21
4	3.0	1.0	7	21	28
5	4.0	1.0	8	31	39
6	5.0	1.0	8	32	40
7	6.0	1.0	8	33	41
8	8.0	1.0	6	31	37

9	10.0	1.0	5	33	38
10	12.0	1.0	4	30	34
11	6.0	0.5	4	28	32
12	6.0	2.0	10	37	47
13	6.0	4.0	18	36	54
14	6.0	6.0	19	19	38
15	6.0	8.0	21	10	31
16 ^b	6.0	2.0	14	35	49

Reaction conditions: 1st step) pyrrolidine, THF (0.2 mL), HOAc, rt, 5 mins; 2nd step) DOH (0.1 mmol), THF (0.3 mL), 66 °C, overnight. ^aYield determined by GC using dodecane as internal standard. ^b1,4-dioxane as solvent instead of THF.

General procedure for Table S6: to a 4 mL vial was added pyrrolidine, THF (0.2 mL), and HOAc. After stirring at room temperature for 5 mins, the mixture was injected to the solution of DOH (0.1 mmol, 13 mg) in THF (0.3 mL) at 66 °C. The reaction was stirred at 66 °C overnight. After cooling down to room temperature, dodecane was added as internal standard for GC measurement.

Table S7. Optimization of pyrrolidine and TFA for 3a and 2a




Entry	Pyrrolidine (equiv)	TFA (equiv)	3a (%)	2a (%)	Total (%) ^a
1	1.0	1.0	6	1	7
2	2.0	1.0	9	2	11
3	3.0	1.0	25	6	31
4	4.0	1.0	32	10	42
5	6.0	1.0	41	25	66
6	8.0	1.0	18	23	41
7	10.0	1.0	16	26	42
8	12.0	1.0	13	23	36
11 ^b	4.0	1.0	36	5	41
12 ^b	6.0	1.0	61	11	72
13	2.0	2.0	6	1	7
14	4.0	2.0	20	5	25
15	6.0	2.0	31	13	44
16	8.0	2.0	29	22	51
17	10.0	2.0	24	19	43
18	12.0	2.0	12	25	37

Reaction conditions: 1st step) pyrrolidine, THF (0.2 mL), TFA, rt, 5 mins; 2nd step) DOH (0.1 mmol), THF (0.3 mL), 66 °C, overnight. ^aYield determined by GC using dodecane as internal standard. ^b1,4-dioxane, 101 °C.

General procedure for Table S7: to a 4 mL vial was added pyrrolidine, THF (0.2 mL), and TFA. After stirring at room temperature for 5 mins, the mixture was injected to the solution of DOH (0.1 mmol, 13 mg) in THF (0.3 mL) at 66 °C. The reaction was stirred at 66 °C overnight. After cooling down to room temperature, dodecane was added as internal standard for GC measurement.


7. General procedures for the reactions of DOH and Amines

7.1. Reactions of DOH and amines catalyzed by HOAc



1,4-Dipyrrolidinylbenzene (2a). To a 4 mL vial was added pyrrolidine (6.0 equiv., 480 μ L), a magnetic stirring bar, THF (2 mL), and HOAc (2.0 equiv., 120 μ L). After stirring at room temperature for 5 mins, the mixture was added to the solution of DOH in THF (3 mL) in a 35 mL pressure tube at 66 °C. The reaction was stirred at 66 °C overnight. After cooling down to room temperature, the solvent was evaporated. Column chromatography (SiO₂, EA/cyclohexane = 2/23) afforded the desired **2a** as a white solid in 42% yield (90 mg). ¹H NMR (300 MHz, *d*₈-toluene): δ (ppm) 6.64 (brs, 4H), 3.02 (brs, 8H), 1.66-1.62 (m, 8H). HRMS (ESI) *m/z* calcd. for C₁₄H₂₁N₂⁺ [M+H]⁺: 217.1705, found: 217.1702. Because of the facile oxidation of **2a** to the radical cation analogous to the formation of Würster's salt,³ its NMR spectroscopy cannot be properly conducted. To the solution of **2a** in acetone was added two drops of HCl (aq. 37%). **2a**·2HCl was obtained as needle crystal after evaporation. ¹H NMR (300 MHz, CD₃OD) δ (ppm) 7.54 (brs, 4H), 3.71-3.66 (m, 8H), 2.28-2.23 (m, 8H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 141.0, 121.7, 57.0, 25.1. ¹H NMR (300 MHz, *d*₈-toluene): δ (ppm) 6.64 (brs, 4H), 3.02 (brs, 8H), 1.66-1.62 (m, 8H). HRMS (ESI) *m/z* calcd. for C₁₄H₂₁N₂⁺ [M+H]⁺: 217.1705, found: 217.1702. Because of the facile oxidation of **2a** to the radical cation analogous to the formation of Würster's salt,³ its NMR spectroscopy cannot be properly conducted. To the solution of **2a** in acetone was added two drops of HCl (aq. 37%). **2a**·2HCl was obtained as needle crystal after evaporation. ¹H NMR (300 MHz, CD₃OD) δ (ppm) 7.54 (brs, 4H), 3.71-3.66 (m, 8H), 2.28-2.23 (m, 8H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 141.0, 121.7, 57.0, 25.1.


4-Pyrrolidinylphenol (3a). From the above-mentioned reaction mixture, column chromatography (SiO₂, EA/cyclohexane = 3/17) furthermore afforded the desired **3a** as yellow crystals (18 mg, yield: 11%). ¹H NMR (300 MHz, *d*₆-DMSO) δ (ppm) 8.42 (s, 1H), 6.63-6.60 (m, 2H), 6.41-6.38 (m, 2H), 3.12-3.08 (m, 4H), 1.93-1.88 (m, 4H). ¹³C NMR (75 MHz, *d*₆-DMSO) δ (ppm) 147.9, 141.8, 115.8, 112.8, 48.0, 24.8. HRMS (ESI) *m/z* calculated for C₁₀H₁₄NO⁺ [M+H]⁺: 164.1075, Found 164.1075.




4-Bis(2-methylpyrrolidinyl)benzene (2b). To a 35 mL pressure tube was added 2-methylpyrrolidine (4.0 equiv., 1632 μ L), a magnetic stirring bar, THF (8 mL), and HOAc (2.0 equiv., 480 μ L). After stirring at room temperature for 5 mins, the mixture was added to the solution of DOH (4.0 mmol, 532 mg) in THF (12 mL) in a 35 mL pressure tube at 66 °C. The reaction was stirred at 66 °C overnight.

After cooling down to room temperature, the solvent was evaporated. Column chromatography (SiO₂, EA/cyclohexane = 2/23) afforded the desired 4-bis(2-methylpyrrolidinyl)benzene as a yellow solid (mixture of diastereomers, 80 mg, yield: 8%). ¹H NMR (300 MHz, *d*₆-benzene) δ (ppm) 6.74-6.73 (s, 4H), 3.71-3.62 (m, 2H), 3.32-3.26 (m, 2H), 3.03-2.95 (m, 2H), 1.84-1.70 (m, 4H), 1.64-1.54 (m, 2H), 1.40-1.34 (m, 2H), 1.11-1.08 (d, 6H). ¹³C NMR (300 MHz, *d*₆-benzene) δ (ppm) 140.0, 114.4, 54.3, 49.5, 33.5, 23.6, 20.0. HRMS (ESI) *m/z* calculated for C₁₆H₂₅N₂⁺ [M+H]⁺: 245.2018, Found 245.2014.


4-(2-Methylpyrrolidinyl)phenol (3b). From the above reaction mixture, column chromatography (SiO₂, EA/cyclohexane = 3/17) furthermore afforded desired 4-(2-methylpyrrolidinyl)phenol as orange crystals (53 mg, yield: 7%). ¹H NMR (300 MHz, *d*₆-DMSO) δ (ppm) 8.40 (s, 1H), 6.63-6.59 (m, 2H), 6.39 (d, *J* = 8.8 Hz, 2H), 3.74-3.64 (m, 1H), 3.30-3.24 (m, 1H), 3.01-2.93 (m, 1H), 2.02-1.85 (m, 3H), 1.63-1.58 (m, 1H), 1.05 (d, *J* = 6.2 Hz, 3H). ¹³C NMR (75 MHz, *d*₆-DMSO) δ (ppm) 148.2, 141.2, 116.3, 113.3, 53.9, 49.0, 33.2, 23.3, 19.8. HRMS (ESI) *m/z* calculated for C₁₁H₁₆NO⁺ [M+H]⁺: 178.1232, Found 178.1236.




1,1'-(1,4-Phenylene)bis(pyrrolidin-3-ol) (2c). From reaction of DOH (0.5 mmol, 64 mg) and (*R*)-3-pyrrolidinol (**1c**, 6.0 equiv, 240 μ L) in 1,4-dioxane (2.5 mL) at 101 °C overnight, 40 mg (32%) of white crystal **2c** was obtained after column chromatography (SiO₂, EA). To the solution of **2c** in acetone was added two drops of HCl (aq. 37%). **2c**·2HCl was obtained after evaporation. ¹H NMR (300 MHz, CD₃OD) δ (ppm) 7.20 (s, 4H), 4.69 – 4.60 (m, 2H), 3.79 – 3.68 (m, 4H), 3.67 – 3.58 (m, 2H), 3.48 – 3.41 (m, 2H), 2.40 – 2.25 (m, 2H), 2.19 – 2.10 (m, 2H). ¹³C NMR (75 MHz, *d*₆-DMSO) δ (ppm) 138.8, 117.3, 69.2, 60.7, 51.7, 34.0. HRMS (ESI) *m/z* calculated for C₁₄H₂₁N₂O₂⁺ [M+H]⁺: 249.1603, Found 249.1606.



1-(4-hydroxyphenyl)pyrrolidin-3-ol (3c). From the same reaction for the preparation of **2c** from DOH (0.5 mmol, 64 mg) and (*R*)-3-pyrrolidinol (**1c**, 6.0 equiv, 240 μ L) in 1,4-dioxane (2.5 mL) at 101 °C overnight, 30 mg (34%) of orange crystal **3c** was obtained after column chromatography (SiO₂, EA/cyclohexane = 1/1). ¹H NMR (300 MHz, CD₃OD) δ (ppm) 6.79 – 6.63 (m, 2H), 6.55 – 6.39 (m, 2H), 4.52 – 4.45 (m, 1H), 3.49 – 3.32 (m, 2H), 3.26 – 3.14 (m, 1H), 3.14 – 3.03 (m, 1H), 2.22 – 2.08 (m, 1H), 2.01 – 1.90 (m, 1H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 149.2, 143.9, 116.9, 114.2, 71.9, 47.6, 35.0. HRMS (ESI) *m/z* calculated for C₁₀H₁₄NO₂⁺ [M+H]⁺: 180.1024, Found 180.1026.




1,1'-(1,4-Phenylene)bis(*N,N*-dimethylpyrrolidin-3-amine) (2d). From the reaction of DOH (0.5 mmol, 64 mg) and *N,N*-dimethylpyrrolidin-3-amine (**1d**, 6.0 equiv, 381 μ L) in 1,4-dioxane (2.5 mL) at 101 °C overnight, 120 mg (57%) of brown oil **2d**·HOAc was obtained after column chromatography (reverse-SiO₂, methanol). ¹H NMR (300 MHz, *d*₈-toluene) δ (ppm) 10.43 (s, 2H), 6.56 (s, 4H), 3.25 – 3.14 (m, 4H), 3.14 – 3.06 (m, 2H), 3.04 – 2.94 (m, 2H), 2.68 – 2.54 (m, 2H), 2.04 (s, 12H), 1.89 (s, 6H), 1.81 – 1.70 (m, 4H). ¹³C NMR (75 MHz, *d*₈-toluene) δ (ppm) 174.2, 140.8, 113.7, 65.4, 52.3, 47.8, 42.8, 29.1, 21.5. HRMS (ESI) *m/z* calculated for C₁₈H₃₁N₄⁺ [M+H]⁺: 303.2549, Found 303.2549.




4-(3-(dimethylamino)pyrrolidin-1-yl)phenol (3d). From the same reaction for the preparation of **2d** from DOH (0.5 mmol, 64 mg) and *N,N*-dimethylpyrrolidin-3-amine (**1d**, 6.0 equiv, 381 μ L) in 1,4-dioxane (2.5 mL) at 101 °C overnight, 11 mg (11%) of orange crystal **3d** was obtained after column chromatography (SiO₂, MeOH/CH₂Cl₂ = 1/19). ¹H NMR (300 MHz, CD₃OD) δ (ppm) 6.76 – 6.63 (m, 2H), 6.57 – 6.42 (m, 2H), 3.41 (dd, *J* = 8.8, 7.2 Hz, 1H), 3.35 – 3.28 (m, 1H), 3.27 – 3.17 (m, 1H), 3.12– 3.04 (m, 1H), 3.02 – 2.87 (m, 1H), 2.33 (s, 6H), 2.27 – 2.16 (m, 1H), 1.98 – 1.80 (m, 1H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 149.5, 143.6, 116.9, 114.3, 66.8, 53.8, 48.8, 44.1, 30.6. HRMS (ESI) *m/z* calculated for C₁₂H₁₉N₂O⁺ [M+H]⁺: 207.1497, Found 207.1501.


7.2. Reactions of DOH and amines catalyzed by TFA




General procedures: To a 35 mL pressure tube was added DOH (1.0 mmol, 128 mg), a magnetic stirring bar, and 1,4-dioxane (5 mL). To the solution was added amine (6.0 equiv) and TFA (1.0 equiv, 80 μ L). The reaction was stirred at 101 °C overnight. After cooling down to room temperature and removal of solvent by evaporation, the reaction mixture was purified by column chromatography (SiO₂).




1,4-Dipyrrolidinylbenzene (2a). From reaction of DOH and pyrrolidine (**1a**, 6.0 equiv, 480 μ L), 35 mg (13%) of white solid **2a** was obtained after column chromatography (SiO₂, EA/cyclohexane = 2/23).




4-Pyrrolidinylphenol (3a). From the same reaction for the preparation of **2a** from DOH and pyrrolidine (**1a**, 6.0 equiv, 480 μ L), 95 mg (58%) of yellow crystal **3a** was obtained after furthermore column chromatography (SiO₂, EA/cyclohexane = 3/17).




1,1'-(1,4-Phenylene)bis(pyrrolidin-3-ol) (2c). From reaction of DOH and (*R*)-3-pyrrolidinol (**1c**, 6.0 equiv, 480 μ L), 43 mg (13%) of white crystal **2c** was obtained after column chromatography (SiO₂, EA).




1-(4-hydroxyphenyl)pyrrolidin-3-ol (3c). From the same reaction for the preparation of **2c** from DOH and (*R*)-3-pyrrolidinol (**1c**, 6.0 equiv, 480 μ L), 105 mg (59%) of orange crystal **3c** was obtained after column chromatography (SiO₂, EA/cyclohexane = 1/1).



1,1'-(1,4-Phenylene)bis(*N,N*-dimethylpyrrolidin-3-amine) (2d). From the reaction of DOH (0.5 mmol, 64 mg) and *N,N*-dimethylpyrrolidin-3-amine (**1d**, 6.0 equiv, 381 μ L), 50 mg (33%) of brown oil **2d** was obtained after column chromatography (reverse-SiO₂, methanol).




4-(3-(dimethylamino)pyrrolidin-1-yl)phenol (3d). From the same reaction for the preparation of **2d** from DOH (0.5 mmol, 64 mg) and *N,N*-dimethylpyrrolidin-3-amine (**1d**, 6.0 equiv, 381 μ L), 57 mg (55%) of orange crystal **3d** was obtained after column chromatography (SiO₂, MeOH/CH₂Cl₂ = 1/19).




4-(3-Methylpiperidin-1-yl)phenol (3e). From the reaction of DOH and 3-methylpiperidine (**1e**, 6.0 equiv, 710 μ L), 85 mg (45%) of white solid **3e** was obtained after column chromatography (SiO₂, EA/cyclohexane = 1/4). ¹H NMR (300 MHz, CD₃OD) δ (ppm) 6.92 – 6.85 (m, 2H), 6.74 – 6.67 (m, 2H), 3.37 – 3.26 (m, 2H), 2.54 – 2.41 (m, 1H), 2.17 (dd, *J* = 11.7, 10.3 Hz, 1H), 1.86 – 1.65 (m, 4H), 1.06 – 0.95 (m, 1H), 0.94 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 153.1, 146.7, 121.0, 116.6,


61.8, 53.8, 33.8, 32.4, 26.6, 19.9. HRMS (ESI) m/z calculated for $C_{12}H_{18}NO^+$ $[M+H]^+$: 192.1388, Found 192.1390.




4-(Piperidin-1-yl)phenol (3f). From the reaction of DOH and piperidine (**1f**, 6.0 equiv, 533 μ L), 37 mg (21%) of white crystal **3f** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/4). 1H NMR (300 MHz, $CDCl_3$) δ (ppm) 6.87 (d, J = 9.1 Hz, 2H), 6.71 (d, J = 9.1 Hz, 2H), 3.01 (t, J = 5.4 Hz, 4H), 1.78 – 1.67 (m, 4H), 1.60 – 1.47 (m, 2H). ^{13}C NMR (75 MHz, $CDCl_3$) δ (ppm) 150.0, 146.6, 119.4, 116.0, 52.8, 26.1, 24.2. HRMS (ESI) m/z calculated for $C_{11}H_{16}NO^+$ $[M+H]^+$: 178.1232, Found 178.1233.



4-(4-Methylpiperidin-1-yl)phenol (3g). From the reaction of DOH and 4-methylpiperidine (**1g**, 6.0 equiv, 710 μ L), 32 mg (21%) of yellow oil **3g** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/4). 1H NMR (300 MHz, CD_3OD) δ (ppm) 6.99 – 6.81 (m, 2H), 6.82 – 6.60 (m, 2H), 3.41 – 3.32 (m, 2H), 2.66 – 2.48 (m, 2H), 1.83 – 1.68 (m, 2H), 1.46 – 1.25 (m, 3H), 0.98 (d, J = 6.2 Hz, 3H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 153.1, 146.6, 121.0, 116.6, 53.8, 35.4, 31.7, 22.2. HRMS (ESI) m/z calculated for $C_{12}H_{18}NO^+$ $[M+H]^+$: 192.1388, Found 192.1389.




4-Morpholinophenol (3h). From the reaction of DOH and morpholine (**1h**, 6.0 equiv, 517 μ L), 84 mg (21%) of white crystal **3h** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/3). 1H NMR (300 MHz, CD_3OD) δ (ppm) 6.89 – 6.80 (m, 2H), 6.76 – 6.69 (m, 2H), 3.82 – 3.76 (m, 4H), 2.99 – 2.93 (m, 4H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 152.9, 146.0, 119.6, 116.7, 68.01 52.6. HRMS (ESI) m/z calculated for $C_{10}H_{14}NO_2^+$ $[M+H]^+$: 180.1024, Found 180.1022.




1,4-bis(2,6-dimethylmorpholino)benzene (2i). From the reaction of DOH and morpholine (**1i**, mixture of *cis* and *trans* isomers, 6.0 equiv, 740 μ L), 29 mg (10%) of yellow solid **2i** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/9). 1H NMR (300 MHz, C_6D_6 , isomer **2ia**) δ (ppm) 6.87 (s, 4H), 3.80 – 3.68 (m, 4H), 3.22 – 3.14 (m, 4H), 2.30 (dd, J = 11.9, 10.2 Hz, 4H), 1.13 (d, J = 6.3 Hz, 12H). ^{13}C NMR (75 MHz, C_6D_6 , isomer **2ia**) δ (ppm) 145.9, 118.0, 72.0, 56.7, 19.3. 1H NMR (300 MHz, C_6D_6 , isomer **2ib**) δ (ppm) δ 6.90 – 6.79 (m, 4H), 4.08 – 3.95 (m, 2H), 3.79 – 3.66 (m, 2H), 3.17 (ddd,


$J = 10.8, 2.4, 1.1$ Hz, 2H), 2.95 (ddd, $J = 11.4, 3.3, 1.0$ Hz, 2H), 2.61 (ddd, $J = 11.6, 5.9, 1.1$ Hz, 2H), 2.34 – 2.23 (m, 2H), 1.23 (d, $J = 6.4$ Hz, 6H), 1.12 (d, $J = 6.2$ Hz, 6H). ^{13}C NMR (75 MHz, C_6D_6 , isomer **2ib**) δ (ppm) 146.6, 146.0, 118.3, 118.1, 71.9, 66.6, 56.7, 56.2, 19.3, 18.3. HRMS (ESI) m/z calculated for $\text{C}_{18}\text{H}_{29}\text{N}_2\text{O}_2^+$ $[\text{M}+\text{H}]^+$: 305.2229, Found 305.2232.



4-(2,6-Dimethylmorpholino)phenol (3i). From the reaction for the preparation of **2i** from DOH and morpholine (**1i**, mixture of *cis* and *trans* isomers, 6.0 equiv, 740 μL), 96 mg (47%, 21 mg and 76 mg respectively) of yellow oil **3i** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/9). ^1H NMR (300 MHz, CD_3OD , isomer **3ia**) δ (ppm) 6.87 – 6.77 (m, 2H), 6.77 – 6.64 (m, 2H), 4.17 – 4.04 (m, 2H), 3.02 (ddd, $J = 11.6, 3.3, 1.1$ Hz, 2H), 2.71 (ddd, $J = 11.6, 5.9, 1.1$ Hz, 2H), 1.29 (d, $J = 6.5$ Hz, 6H). ^{13}C NMR (75 MHz, CD_3OD , isomer **3ia**) δ (ppm) 152.6, 146.6, 119.8, 116.7, 68.1, 57.6, 18.2. HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{18}\text{NO}_2^+$ $[\text{M}+\text{H}]^+$: 208.1337, Found 208.1333. ^1H NMR (300 MHz, CD_3OD , isomer **3ib**) δ (ppm) 6.88 – 6.80 (m, 2H), 6.75 – 6.68 (m, 2H), 3.85 – 3.70 (m, 2H), 3.30 – 3.24 (m, 2H), 2.31 – 2.18 (m, 2H), 1.19 (d, $J = 6.3$ Hz, 6H). ^{13}C NMR (75 MHz, CD_3OD , isomer **3ib**) 152.9, 145.7, 119.8, 116.7, 73.1, 58.2, 19.2. HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{18}\text{NO}_2^+$ $[\text{M}+\text{H}]^+$: 208.1337, Found 208.1335.




Methyl 1-(4-hydroxyphenyl)piperidine-4-carboxylate (3j). From the reaction of DOH and methyl piperidine-4-carboxylate (**1j**, 6.0 equiv, 810 μL), 81 mg (35%) of white crystal **3j** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/4). ^1H NMR (300 MHz, CD_3OD) δ (ppm) 6.96 – 6.82 (m, 2H), 6.80 – 6.61 (m, 2H), 3.69 (s, 3H), 3.42 – 3.33 (m, 2H), 2.65 (ddd, $J = 12.2, 11.1, 2.8$ Hz, 2H), 2.44 (tt, $J = 11.3, 4.1$ Hz, 1H), 2.05 – 1.94 (m, 2H), 1.92 – 1.73 (m, 2H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 177.1, 153.2, 146.4, 121.0, 116.6, 52.8, 52.2, 41.8, 29.5. HRMS (ESI) m/z calculated for $\text{C}_{13}\text{H}_{18}\text{NO}_3^+$ $[\text{M}+\text{H}]^+$: 236.1286, Found 236.1292.




1-(4-Hydroxyphenyl)piperidine-4-carbonitrile (3k). From the reaction of DOH and piperidine-4-carbonitrile (**1k**, 6.0 equiv, 670 μL), 98 mg (35%) of white crystal **3k** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 7/13). ^1H NMR (300 MHz, CD_3OD) δ (ppm) 6.91 – 6.82 (m, 2H), 6.75 – 6.67 (m, 2H), 3.26 – 3.14 (m, 2H), 2.94 – 2.80 (m, 3H), 2.11 – 2.00 (m, 2H), 1.98 – 1.85 (m,


2H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 153.3, 146.2, 122.9, 121.0, 116.6, 51.4, 30.0, 26.9. HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}^+$ $[\text{M}+\text{H}]^+$: 203.1184, Found 203.1188.




1-(4-Hydroxyphenyl)piperidin-3-ol (3l). From the reaction of DOH and piperidin-3-ol (**1l**, 6.0 equiv, 610 mg), 82 mg (42%) of white crystal **3l** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/1). ^1H NMR (300 MHz, CD_3OD) δ (ppm) 6.91 – 6.84 (m, 2H), 6.74 – 6.66 (m, 2H), 3.85 – 3.73 (m, 1H), 3.40 – 3.33 (m, 1H), 3.23 – 3.14 (m, 1H), 2.60 (ddd, J = 11.7, 10.5, 3.1 Hz, 1H), 2.50 (dd, J = 11.1, 8.8 Hz, 1H), 2.02 – 1.91 (m, 1H), 1.91 – 1.80 (m, 1H), 1.75 – 1.59 (m, 1H), 1.41 – 1.30 (m, 1H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 153.0, 146.4, 121.0, 116.6, 68.1, 60.6, 53.3, 33.7, 24.4. HRMS (ESI) m/z calculated for $\text{C}_{11}\text{H}_{16}\text{NO}_2^+$ $[\text{M}+\text{H}]^+$: 194.1181, Found 194.1184.



4-(3-(Hydroxymethyl)piperidin-1-yl)phenol (3m). From the reaction of DOH and piperidin-3-ylmethanol (**1m**, 6.0 equiv, 690 mg), 51 mg (25%) of yellowish solid **3m** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 3/2). ^1H NMR (300 MHz, CD_3OD) δ (ppm) 6.95 – 6.86 (m, 2H), 6.76 – 6.67 (m, 2H), 3.55 – 3.38 (m, 3H), 3.38 – 3.31 (m, 1H), 2.61 – 2.49 (m, 1H), 2.32 (dd, J = 11.6, 10.3 Hz, 1H), 1.96 – 1.83 (m, 1H), 1.83 – 1.67 (m, 3H), 1.14 – 1.00 (m, 1H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 153.1, 146.8, 121.0, 116.6, 66.3, 57.3, 54.2, 40.3, 28.1, 26.1. HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{18}\text{NO}_2^+$ $[\text{M}+\text{H}]^+$: 208.1337, Found 208.1337.




4-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)phenol (3n). From the reaction of DOH and 1,4-dioxo-8-azaspiro[4.5]decan-8-yl (**1n**, 6.0 equiv, 769 μL), 56 mg (24%) of yellow crystal **3n** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/3). ^1H NMR (300 MHz, CDCl_3) δ (ppm) 6.90 – 6.81 (m, 2H), 6.76 – 6.63 (m, 2H), 3.98 (s, 4H), 3.16 (t, J = 5.7 Hz, 4H), 1.87 (t, J = 5.8 Hz, 4H). ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 150.3, 145.2, 119.6, 116.0, 107.2, 64.4, 49.8, 34.8. HRMS (ESI) m/z calculated for $\text{C}_{13}\text{H}_{18}\text{NO}_3^+$ $[\text{M}+\text{H}]^+$: 236.1286, Found 236.1292.




Ethyl 1-(4-hydroxyphenyl)piperidine-3-carboxylate (3o). From the reaction of DOH and ethyl piperidine-3-carboxylate (**1o**, 6.0 equiv, 932 μL), 67 mg (27%) of yellow solid **3o** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 1/4). ^1H NMR (300 MHz, CDCl_3) δ (ppm) 6.97 – 6.82 (m, 2H), 6.82 – 6.69 (m, 2H), 4.18 (q, J = 7.1 Hz, 2H), 3.59 – 3.49 (m, 1H), 3.30 (dd, J = 12.2, 3.9 Hz, 1H).


Hz, 1H), 2.90 (dd, $J = 11.9, 9.8$ Hz, 1H), 2.80 – 2.65 (m, 2H), 2.07 – 1.97 (m, 1H), 1.91 – 1.69 (m, 2H), 1.69 – 1.55 (m, 1H), 1.29 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 174.5, 150.6, 145.7, 119.8, 116.0, 60.8, 54.2, 51.9, 41.8, 26.8, 24.5, 14.3. HRMS (ESI) m/z calculated for $\text{C}_{14}\text{H}_{20}\text{NO}_3^+$ $[\text{M}+\text{H}]^+$: 250.1443, Found 250.1447.



4-(Octahydroisoquinolin-2(1H)-yl)phenol (3p). From the reaction of DOH and decahydroisoquinoline (**1p**, 6.0 equiv, 890 μL), 92 mg (25%) of yellow crystal **3p** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 3/17). ^1H NMR (300 MHz, CD_3OD) δ (ppm) 6.93 – 6.85 (m, 2H), 6.75 – 6.65 (m, 2H), 3.42 (ddt, $J = 11.6, 4.1, 2.3$ Hz, 1H), 3.25 (ddd, $J = 11.3, 3.7, 2.1$ Hz, 1H), 2.59 (ddd, $J = 12.7, 11.7, 2.9$ Hz, 1H), 2.24 (t, $J = 11.2$ Hz, 1H), 1.81 – 1.74 (m, 2H), 1.71 – 1.57 (m, 3H), 1.51 – 1.40 (m, 1H), 1.39 – 1.27 (m, 4H), 1.12 – 0.95 (m, 3H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 153.1, 146.54, 121.0, 116.6, 60.2, 54.3, 43.1, 42.8, 34.1, 34.1, 31.6, 27.5, 27.2. HRMS (ESI) m/z calculated for $\text{C}_{15}\text{H}_{22}\text{NO}^+$ $[\text{M}+\text{H}]^+$: 232.1701, Found 232.1701.





4-(4-Methylpiperazin-1-yl)phenol (3q). From the reaction of DOH (0.5 mmol, 64 mg) and 1-methylpiperazine (**1q**, 6.0 equiv, 335 μL), 35 mg (36%) of yellow crystal **3q** was obtained after column chromatography (SiO_2 , MeOH/ CH_2Cl_2 = 1/9). ^1H NMR (300 MHz, CD_3OD) δ (ppm) 6.90 – 6.83 (m, 2H), 6.75 – 6.68 (m, 2H), 3.10 – 3.01 (m, 4H), 2.68 – 2.60 (m, 4H), 2.35 (s, 3H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 153.1, 145.7, 120.1, 116.7, 56.0, 51.8, 46.0. HRMS (ESI) m/z calculated for $\text{C}_{11}\text{H}_{17}\text{N}_2\text{O}^+$ $[\text{M}+\text{H}]^+$: 193.1341, Found 193.1346.




tert-Butyl 4-(4-hydroxyphenyl)piperazine-1-carboxylate (3r). From the reaction of DOH and tert-butyl piperazine-1-carboxylate (**1r**, 6.0 equiv, 1.1 g), 89 mg (32%) of yellow oil **3r** was obtained after column chromatography (SiO_2 , EA/cyclohexane = 3/17). ^1H NMR (300 MHz, CD_3OD) δ (ppm) 6.90 – 6.82 (m, 2H), 6.77 – 6.66 (m, 2H), 3.54 (t, $J = 5.2$ Hz, 4H), 2.97 – 2.91 (m, 4H), 1.47 (s, 9H). ^{13}C NMR (75 MHz, CD_3OD) δ (ppm) 156.4, 153.3, 146.0, 120.6, 116.7, 81.3, 52.6, 28.7. HRMS (ESI) m/z calculated for $\text{C}_{15}\text{H}_{23}\text{N}_2\text{O}_3^+$ $[\text{M}+\text{H}]^+$: 279.1709, Found 279.1714.

8. Mechanism studies



8.1. The reaction of DOH and pyrrolidine at room temperature




GC-MS for III:





8.2. The reaction of DOH and piperidine at room temperature




GC-MS for S13:



8.3. The reaction of DOH and piperidine at 40°C



GC-MS for S14:



9. Drug molecules containing *N*-phenylpiperizinyll moiety⁴⁻⁷





Fig. S1. Drug molecules containing *N*-phenylpiperizinyll moiety.

10. Acid-catalyzed intramolecular Aldol condensation of DOH


Table S8: Screening of various acids for intramolecular aldol condensation of DOH



Entry	Acid	<i>t</i>	Yield ^a
1	BF ₃ ·2H ₂ O, 2.0 equiv	5 h	2%
2	Sc(OTf) ₃ , 1.0 equiv	1.5 h	n.d.
3	Yb(OTf) ₃ , 1.0 equiv	1.5 h	n.d.
4	In(OTf) ₃ , 1.0 equiv	1.5 h	n.d.
5	HCOOH, 2.0 equiv	26 h	1%
6	HOAc, 2.0 equiv	1 h	n.d.
7	TFA, 2.0 equiv	26 h	5%
8	HCl, 2.0 equiv	24 h	2%
9 ^b	Sc(OTf) ₃ , 10 mol%	19 h	n.d.
10 ^b	Yb(OTf) ₃ , 10 mol%	19 h	n.d.
11 ^b	In(OTf) ₃ , 10 mol%	19 h	n.d.
12 ^b	Cu(OTf) ₂ , 2.0 equiv	19 h	n.d.
13 ^c	Amberlyst-15, 50% (w/w)	8 h	n.d.
14 ^d	HOTf, 0.2 equiv	22 h	n.d.
15 ^e	PTSA, 2.0 equiv	1 h	n.d.

Reaction conditions: DOH (0.2 mmol, 0.5 M), Acid, H₂O (0.4 mL), 100 °C. ^aYield determined by ¹H NMR using 1,4-dinitrobenzene as reference. ^bDOH (0.2 M). ^cDOH (0.1 M). ^dDOH (0.02 M). ^eXylene (1.0 mL) instead of H₂O, 140 °C.

Table S9: Effect of the concentration of DOH/TFA for intramolecular aldol condensation of DOH




Entry	Conc. (DOH)	Conc. (TFA)	<i>t</i> (h)	Yield (%) ^a
1	0.2 M	0.4 M	0.5	14 (12) ^b
2	0.2 M	0.4 M	1	19
3	0.1 M	0.2 M	0.5	17
4	0.02 M	0.2 M	1	20
5	0.01 M	0.2 M	1	32
6	0.003M	0.2 M	1	28
7	0.003M	0.2 M	16	26

Reaction conditions: DOH (0.2 mmol), TFA, Xylene, 140 °C. ^aYield was measured by ¹H NMR using 1,4-dinitrobenzene as reference. ^bIsolated yield in 2.0 mmol scale.

General procedure for Table S8-9: to a 4 mL pressure tube was added DOH (0.2 mmol, 26 mg), solvent, a magnetic stirring bar, and acid. The pressure tube was sealed and stirred at the specified temperature. After cooling down to room temperature, the solvent was evaporated. 1,4-dinitrobenzene was added as reference, and the mixture was analyzed *via* ¹H NMR measurement.

Hydroquinone (2.0 mmol scale reaction in entry 2). To a 35 mL pressure tube was added DOH (2.0 mmol, 256 mg), xylene (10 mL), and a magnetic stirring bar. To the solution was added TFA (2.0 equiv., 306 μ L), and the reaction was stirred at 140 °C for 30 mins. After cooling down to room temperature, the solvent was evaporated. Column chromatography (SiO₂, EA/cyclohexane = 1/4) afforded hydroquinone as a white solid (26 mg, yield: 12%). ¹H NMR (300 MHz, CD₃OD): δ (ppm) 6.62 (s, 4H). HRMS (EI): calculated for C₆H₆O₂ 110.03623, Found 110.03602.


Table S10: TFA-catalyzed intramolecular aldol condensation of DOH under high temperature



Entry	<i>T</i> (°C)	<i>P</i> (N ₂)	<i>t</i>	Yield (%) ^a
1 ^b	100	1.01 bar	19 h	7
2	150	30 bar	1 h	9
3	200	16 bar	1 h	19
4	200	16 bar	2 h	23
5	250	40 bar	1 h	27
6	265	56 bar	1 h	32
7 ^c	150	30 bar	1 h	16
8 ^c	207	5 bar	1 h	23

Reaction conditions: DOH (0.05 M), TFA (2.0 equiv), H₂O (2 mL), temp. N₂. ^aYield determined by ¹H NMR using 1,4-dinitrobenzene as reference. ^bDOH (0.1 M), Ar instead of N₂. ^cXylene (2 mL).

General procedure for Table S10: to a 4 mL vial was added DOH (0.1 mmol, 13 mg), a magnetic stirring bar, solvent, and TFA (2.0 equiv). The vial was sealed by an open-top cap (phenolic) with a septum (PTFE-faced styrene butadiene rubber) pierced with a needle. The vial was placed inside a 300 mL autoclave. The autoclave was flushed with N₂ three times and was subsequently charged with the desired pressure of N₂. The reaction was stirred at the specified temperature. After cooling down to room temperature, the solvent was evaporated. 1,4-dinitrobenzene was added as reference, and the mixture was analyzed *via* ¹H NMR measurement.



***d*₄-Hydroquinone.** To a custom-made autoclave glass insert (height: 6 cm, screw neck: 2 cm, diameter: 6 cm) was added DOH (1.0 mmol, 128 mg), a magnetic stirring bar, D₂O (20 mL), and TFA (2.0 eq., 160 μ L). The insert was sealed by an open-top cap (phenolic) with a septum (PTFE-faced styrene butadiene rubber) pierced with a needle, and then placed inside a 300 mL autoclave. The autoclave was flushed with N₂ three times and charged with 40 bar N₂. The reaction was stirred at 250 °C (the heating mantle was preheated to 250 °C.) for 1 hours. After cooling down to room temperature and removal of the solvent, column chromatography (SiO₂, EA/cyclohexane = 1/4) afforded desired *d*₄-hydroquinone

as yellow solid (9 mg, 8%). ²H NMR (400 MHz, DMSO): δ (ppm) 6.58 (s, 4H). HRMS (EI): calculated for C₆H₂D₄O₂ 114.06134, Found 114.06182.

11. Condition optimization for the conversion of DOA to catechol

Scheme S1. Conversion of HMF to MCO⁸⁻¹⁰






Table S11. Screen of various acids for the conversion of DOA to catechol



Entry	Acid/Base	Time	Yield (%) ^a
1	PTSA·H ₂ O, 2.0 equiv	24 h	16
2	HCl, 2.0 equiv	24 h	18
3	TFA, 2.0 equiv	3 h	6
4	HOAc, 2.0 equiv	5 h	n.d.
5	HOTf, 2.0 equiv	5 h	n.d.
6	H ₂ SO ₄ , 1.0 equiv	24 h	n.d.
7	H ₃ PO ₄ , 1.0 equiv	24 h	n.d.
8	HBF ₄ , 1.0 equiv	24 h	<1
9	CH ₃ SO ₃ H, 1.0 equiv	24 h	n.d.
10	ClSO ₃ H, 1.0 equiv	24 h	n.d.
11	BF ₃ ·2H ₂ O, 2.0 equiv	24 h	n.d.
12 ^b	L-proline, 25 mol%	24 h	n.d.
13 ^c	TBD, 25 mol%	24 h	n.d.

Reaction conditions: DOA (0.2 mmol, 25 mg), H₂O (2 mL), acid or base, 100 °C, under Ar. ^aYield was determined by ¹H NMR using 1,4-dinitrobenzene as reference. ^bH₂O (1 mL), rt. ^cH₂O (4 mL), rt.


Table S12. The effects of solvent and concentration on the conversion of DOA to catechol



Entry	Conc. (DOA)	HCl	Solvent	Yield (%) ^a
1	0.1 M	0.5 equiv	H ₂ O	8
2	0.1 M	1.0 equiv	H ₂ O	10
3	0.1 M	2.0 equiv	H ₂ O	18
4	0.1 M	3.0 equiv	H ₂ O	15
5	0.1 M	4.0 equiv	H ₂ O	14
6	0.05 M	1.0 equiv	H ₂ O	22
7	0.05 M	2.0 equiv	H₂O	34

8	0.05 M	4.0 equiv	H ₂ O	28
9	0.01 M	2.0 equiv	H ₂ O	24
10 ^b	0.05 M	2.0 equiv	Xylene	0
11	0.05 M	2.0 equiv	Dioxane	3
12 ^c	0.05 M	2.0 equiv	1,2-diethoxyethane	2
13 ^d	0.05 M	-	pH = 1.0	14
14 ^d	0.05 M	-	pH = 1.5	16
15 ^{d,e}	0.05 M	-	pH = 1.5	26
16 ^d	0.05 M	-	pH = 2.0	12
17 ^f	0.05 M	-	pH = 2.5 (PBS)	5
18	0.05 M	2.0 equiv	H ₂ O/dioxane	13
19 ^g	0.05 M	2.0 equiv	H ₂ O	35
20 ^h	0.05 M	2.0 equiv	H ₂ O	32

Reaction conditions: DOA (0.2 mmol, 25 mg), solvent, HCl, 100 °C, 24 h, under Ar. ^aYield was determined by ¹H NMR using 1,4-dinitrobenzene as reference. ^b140 °C. ^c125 °C. ^dBuffer solution were prepared by KCl and HCl (0.2 M) in H₂O. ^e5 days. ^fPhosphate buffer solution (0.1 mol/L). ^g*L*-proline (20 mol%). ^h**S1** (20 mol%).




Catechol. To a 25 mL Schlenk flask was added 2-methylcyclopent-2-en-1-one (MCO, 1.0 mmol, 98 μ L), a magnetic stirring bar, DCM (2.5 mL), and a trace amount of Sudan III. A glass pipette (ozone inlet) was inserted into the Schlenk flask and a tube was connected as a gas outlet. The mixture was cooled down to -78 °C and ozone (generated by one Erwin Sander[®] ozonisorator 301.7, flow rate of inlet compressed air was 150 L/h) was bubbled through the reaction. The reaction was stirred at -78 °C for 5 mins until the red reaction solution turned blue. Compressed air was bubbled into the reaction mixture until the solution turned yellow, followed by addition of dimethyl sulfide (200 μ L). After stirring at room temperature for 2 hours, the reaction mixture was diluted with DCM and washed with brine twice. The organic layer was dried over Na₂SO₄ and concentrated to around 1 mL. The obtained DOA solution was used directly for the next step.


To a 50 mL Schlenk flask was added a magnetic stirring bar, degassed H₂O (20 mL), and HCl (37%, 2 equiv, 200 μ L) under Ar. The above solution of DOA was added into the stirred aqueous solution. The reaction was stirred at 100 °C for 24 hours. After cooling down to room temperature and removal of all volatiles *in vacuo*, column chromatography (SiO₂, EA/cyclohexane = 1/4) afforded catechol as a white solid (46 mg, yield: 42%). ¹H NMR (300 MHz, CD₃OD) δ (ppm) 6.78-6.72 (m, 2H), 6.68-6.62 (m, 2H). ¹³C NMR (75 MHz, CD₃OD) δ (ppm) 146.3, 120.9, 116.4. HRMS (EI): calculated for C₆H₆O₂ 110.03623, Found 110.03592.

Appendix I: NMR spectra


^1H -NMR (300 MHz, CD_3OD)




^{13}C -NMR (75 MHz, CD_3OD)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, CD₃OD)




¹H-NMR (300 MHz, *d*₈-toluene)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, *d*₆-DMSO)




¹³C-NMR (75 MHz, *d*₆-DMSO)




¹H-NMR (300 MHz, *d*₆-benzene)




¹³C-NMR (300 MHz, *d*₆-benzene)




¹H-NMR (300 MHz, d₆-DMSO)




¹³C-NMR (75 MHz, d₆-DMSO)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, d₆-DMSO)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, *d*₈-toluene)




¹³C-NMR (75 MHz, *d*₈-toluene)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, CDCl₃)




¹³C-NMR (75 MHz, CDCl₃)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, C₆D₆)




¹³C-NMR (75 MHz, C₆D₆)




¹H-NMR (300 MHz, C₆D₆)




¹³C-NMR (75 MHz, C₆D₆)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)



¹H-NMR (300 MHz, CD₃OD)



¹³C-NMR (75 MHz, CD₃OD)



Chemical structure of 4-(4-cyanophenyl)piperidine: N#CC1CCN(C1)c2ccc(O)cc2

¹H NMR spectrum (CDCl₃) showing peaks and integrations:


Chemical Shift (ppm)	Integration
6.89, 6.87, 6.85, 6.74, 6.72, 6.71, 6.70, 6.69	2.00, 1.96
5.00	
3.16, 3.15, 3.14, 3.13, 3.12, 3.11, 3.10, 3.09, 3.08, 3.07, 3.06, 3.05, 3.04, 3.03, 3.02, 3.01, 3.00, 2.99, 2.98, 2.97, 2.96, 2.95, 2.94, 2.93, 2.92, 2.91, 2.90, 2.89, 2.88, 2.87, 2.86, 2.85, 2.84, 2.83	2.05, 3.03
2.10, 2.08, 2.07, 2.06, 2.05, 2.04, 2.03, 2.02, 2.01, 1.97, 1.96, 1.95, 1.93, 1.92, 1.91, 1.90, 1.89	2.16, 2.02

Chemical structure of 4-(4-hydroxyphenyl)piperidine-4-carbonitrile is shown above the spectrum.


Chemical shift (ppm)

Chemical Shift (ppm)
153.3
146.2
122.9
121.0
116.6
51.4
30.0
26.9


¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)



¹H-NMR (300 MHz, CD₃OD)



¹³C-NMR (75 MHz, CD₃OD)



Oc1ccc(N2CC3CCOC3CC2)cc1

Chemical structure of 4-(4-hydroxyphenyl)-1,3-dioxane is shown. The structure consists of a 1,3-dioxane ring (a six-membered ring with two oxygen atoms) attached to a para-hydroxyphenyl group.

The ¹H NMR spectrum (400 MHz, CDCl₃) shows the following peaks (chemical shift in ppm):

- Aromatic protons: 6.68, 6.85, 6.95, 6.71, 6.82, 6.68 (multiplet, integration 2.00 and 1.98).
- Hydroxyl proton: 3.98 (broad singlet, integration 4.42).
- Methine protons: 3.18, 3.16, 3.14 (multiplet, integration 4.11).
- Methylene protons: 1.88, 1.87, 1.85 (multiplet, integration 4.31).

The spectrum is recorded in CDCl₃, with the solvent peak (CHCl₃) visible at 7.26 ppm.

Chemical structure: Oc1ccc(cc1)N2CCOC3CCOC23

¹³C NMR spectrum (ppm):

- 150.3
- 145.2
- 119.6
- 116.0
- 107.2
- 64.4
- 49.8
- 34.8

Chemical structure of 1-(4-hydroxyphenyl)-4-ethylpiperidine-2-one:

CCOC(=O)C1CCCN(C1)c2ccc(O)cc2

¹H NMR spectrum (CDCl₃) showing peaks from 1.26 to 6.90 ppm. The spectrum includes a broad singlet at 6.89 ppm (OH), a multiplet at 7.0-7.2 ppm (aromatic), a singlet at 4.1 ppm (NH), a multiplet at 2.0-2.3 ppm (CH₂), and a triplet at 1.2 ppm (CH₃). Integration values are provided below the peaks.

Chemical Shift (ppm)	Integration
6.89	1.95
7.0-7.2	2.00
4.1	2.07
2.0-2.3	0.98, 1.02, 0.98, 1.98
1.2	3.32

Chemical structure of 1-(4-hydroxyphenyl)-4-ethoxycarbonylpiperidine and its corresponding ¹³C NMR spectrum.


The chemical structure is 1-(4-hydroxyphenyl)-4-ethoxycarbonylpiperidine, which consists of a piperidine ring substituted with a 4-hydroxyphenyl group and an ethoxycarbonyl group.

The ¹³C NMR spectrum shows the following chemical shifts (ppm):


- 174.5
- 150.6
- 145.7
- 119.8
- 116.0
- 60.8
- 54.2
- 51.9
- 41.8
- 26.8
- 24.5
- 14.3

The spectrum displays a series of peaks corresponding to these chemical shifts, with the most prominent peaks observed in the aromatic region (116.0-150.6 ppm) and the aliphatic region (14.3-60.8 ppm).


¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)




¹H-NMR (300 MHz, CD₃OD)




¹³C-NMR (75 MHz, CD₃OD)



¹H-NMR (300 MHz, CD₃OD)



¹³C-NMR (75 MHz, CD₃OD)



References

- 1 Fulmer, G. R. *et al.* NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist. *Organometallics* **29**, 2176-2179 (2010). <https://doi.org/10.1021/om100106e>
- 2 Wozniak, B., Spannenberg, A., Li, Y., Hinze, S. & de Vries, J. G. Cyclopentanone Derivatives from 5-Hydroxymethylfurfural via 1-Hydroxyhexane-2,5-dione as Intermediate. *ChemSusChem* **11**, 356-359 (2018). <https://doi.org/10.1002/cssc.201702100>
- 3 Grampp, G. *et al.* ESR and ENDOR Investigations on Various Wurster's Radical Cations in Solution. Experimental Results, Theoretical Ab Initio, and DFT Calculations. *Monatshefte für Chemie* **136**, 519-536 (2005). <https://doi.org/10.1007/s00706-004-0224-4>
- 4 Wen, J., Chennamadhavuni, D., Morel, S. R. & Hadden, M. K. Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties. *ACS Medicinal Chemistry Letters* **10**, 1290-1295 (2019). <https://doi.org/10.1021/acsmmedchemlett.9b00188>
- 5 Romanelli, M. N. *et al.* Structure-Affinity Relationships of a Unique Nicotinic Ligand: N-Dimethyl-N4-phenylpiperazinium Iodide (DMPP). *Journal of Medicinal Chemistry* **44**, 3946-3955 (2001). <https://doi.org/10.1021/jm010901y>
- 6 Ouyang, Y. *et al.* Discovery of 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,5-dihydro-4H-[1,2,3]triazolo[4,5-c]quinolin-4-one (CQ211) as a Highly Potent and Selective R1OK2 Inhibitor. *Journal of Medicinal Chemistry* **65**, 7833-7842 (2022). <https://doi.org/10.1021/acs.jmedchem.2c00271>
- 7 Pavletić, P. *et al.* Highly Potent and Selective Dopamine D4 Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma. *Journal of Medicinal Chemistry* (2022). <https://doi.org/10.1021/acs.jmedchem.2c00840>
- 8 Buntara, T. *et al.* Caprolactam from Renewable Resources: Catalytic Conversion of 5-Hydroxymethylfurfural into Caprolactone. *Angew. Chem. Int. Ed.* **50**, 7083-7087 (2011). <https://doi.org/10.1002/anie.201102156>
- 9 Xie, Z.-Y., Deng, J. & Fu, Y. W(OTf)6-Catalyzed Synthesis of γ -Lactones by Ring Contraction of Macrolides or Ring Closing of Terminal Hydroxyfatty Acids in Ionic Liquid. *ChemSusChem* **11**, 2332-2339 (2018). <https://doi.org/10.1002/cssc.201800587>
- 10 Yamazaki, T., Nakai, M. & Kuroki, Y. Process for preparing cyclopentenone derivatives. US patent US3953514A (1974).